Mural Oncology plc (MURA)

Mural Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-119.1	-128.51	-207.45	-189.81	-175.43
Depreciation & Amortization	3.66	3.51	2.57	1.54	1.47
Loss (Gain) From Sale of Assets	3.34	0.1	-	-	-
Asset Writedown & Restructuring Costs	0.92	0.92	-	-	-
Loss (Gain) From Sale of Investments	-0.73	-3.6	-	-	-
Stock-Based Compensation	0.16	5.08	24.11	11.93	11.5
Change in Accounts Receivable	1.39	5.5	-	-	-
Change in Accounts Payable	-12.64	-2.43	-18.25	8.39	5.52
Change in Other Net Operating Assets	2.03	-9.12	4.77	-0.64	0.27
Operating Cash Flow	-118.41	-128.55	-194.25	-168.59	-156.67
Capital Expenditures	-0.04	-0.09	-3.45	-5.51	-4.39
Sale of Property, Plant & Equipment	0.85	0.07	-	-	-
Investment in Securities	65.17	-25.31	-	-	-
Investing Cash Flow	65.98	-25.33	-3.45	-5.51	-4.39
Issuance of Common Stock	0.03	0.2	-	-	-
Other Financing Activities	-	-	468.81	174.1	161.05
Financing Cash Flow	0.03	0.2	468.81	174.1	161.05
Net Cash Flow	-52.41	-153.68	271.11	-	-
Free Cash Flow	-118.45	-128.64	-197.7	-174.1	-161.05
Free Cash Flow Per Share	-6.88	-7.59	-11.85	-10.43	-
Levered Free Cash Flow	-69.64	-82.24	-113.89	-99.81	-
Unlevered Free Cash Flow	-69.64	-82.24	-113.89	-99.81	-
Change in Working Capital	-9.21	-6.05	-13.48	7.75	5.79

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q